| IntroductionIn primary malignant tumor of ovary, 60～90% are epithelial ovarian carcinoma, which is a gynecological malignant tumor with the highest mortality. Because of the delitescence of the clinical symptoms there are over 70% patients belonging to advanced stage when they are diagnosed. Most patients still have progression of disease and recurrence after operation and chemotherapy. The five-year survival rate of epithelial ovarian carcinoma at present wanders between 35% and 40%. However, if ovarian cancer of early stage is detected, it will produce a high five-year survival rate ( 95% ). Therefore, the early diagnosis, etiopathogenisis and pathogenesy of epithelial ovarian carcinoma have become the focus of most reserchers. There are four classes of peroxidases: catalase, superoxide dismutase ( SOD ), glutathione peroxidases ( GPX ) and peroxiredoxins ( Prxs ), which participate in the process of carcinogenesis and the progression of carcinoma. Peoxiredoxin II, as an antioxidative related protein in cells, is the member of Peroxiredoxins (Prxs) family. At present, Prxs have been reported in breast cancer, reneal cancer, lung cancer, carcinoma of oral mucosa, while it hasn't been reported in epithelial ovarian carcinoma. Our research is to investigate the role of Peoxiredoxin II in carcinogenesis and the progression of epithelial ovarian carcinoma.Materials and Methods71 cases including 16 cases of nomal ovarian tissue, 16 cases of benign ovarian tumor, 39 cases of epithelial ovarian carcinoma were obtained from patients who undergone operation for epithelial ovarian carcinoma, ovarian tumor and carcinoma in situ of cervix from Jan 2005 to Oct 2006 in Shengjing hospital. 16 cases of normal ovarian tissue were chosen as control group. The tissue specimens were preserved in liquid nitrogen at -80°C immediately after surgical removal. 39 cases of epithelial ovarian carcinoma included 5 cases of I stage, 8 cases of II stage, 26 cases of III-IV stage. 39 cases of epithelial ovarian carcinoma were composed of 21 cases of serous cystadenocarcinoma, 16 cases of mucous cystadenocarcinoma and 2 cases of other epithelial ovarian carcinoma. There were 9 cases of low differentiation, 10 cases of moderate differentiation and 20 cases of well differentiation in 39 cases of epithelial ovarian carcinoma. The age of the patients with 20 premenopause cases and 19 postmenopause cases ranged from 38 and 69 years and the mean age was 51.3±17.4 years. All patients accepted neither adjuvant radiotherapy, chemotherapy nor hormone therapy before operation. All samples had a definitive pathological diagnosis. The tumor stage was classified according to the International Federation of Gynecology and Obstetics ( FIGO ) 2000 criteria. Western blot were used to investigate the expression of Peroxiredoxin II in 16 cases of nomal ovarian tissue, 16 cases of benign ovarian tumor, 39 cases of ovarian cancer. All data was expressed as mean±standard deviation ((x|-)±s ). SPSS version 11.5 was used to performed statistical analysis, and the differences in data between group were analysis using LSD-test,t-test and one way ANOVA. P <0.05 was considered statistically significant.ResultsWhen we performed Western blot to detect all the samples, we observed a band of 22kD protein among the bands of each sample, which was in close keeping with the molecular weight of 22Kd previously reported by other report. The ratios of gray scale value of purpose bands to internal standards among all cases were evaluated and analyzed.Our findings indicated that Prx II expression in normal ovarian tissue was the highest and Prx II expression in ovarian cancer was the lowest. We found that there was significant relationship of Prx II expression between normal ovarian tissue and ovarian cancer( x~2=6.903, P=0.002).However, it seemed that there was no relationship of Prx II expression between normal ovarian tussie and benign ovarian tumor, between benign ovarian tumor and ovarian cancer. Our findings showed that the expression of Prx II wasn't correlated with clinicopathological parameters ( clinical stage, tumor cell differentiation degree, histopathologic classification) and monpause in ovarian cancer.ConclusionOur findings suggested that Prx II expression in normal ovarian tissue was more than expression of Prx II in ovarian tumor. The expression of Prx II wasn't correlated with clinicopathological parameters ( clinical stage, tumor cell differentiation degree, histopathologic classification) and monpause in ovarian cancer. |
PDF Full Text Request